CGTLive’s Weekly Rewind – July 22, 2022
Review top news and interview highlights from the week ending July 22, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Cell Therapy Trial Fails Primary Endpoint in Treating Muscle Injury After Arthoplasty for Hip Fracture
PLX-PAD is also being studied for the treatment of steroid-refractory chronic graft versus host disease.
2. Craig M. McDonald, MD, on Developing Gene Therapy for Different Populations of DMD
The principal investigator of the HOPE-2 trial discussed results of the trial in the non-ambulatory population of patients with Duchenne muscular dystrophy.
3. Allogeneic CAR T-Cell Therapy Recognized in T-Cell Malignancies
WU-CART-007 has been granted fast track, rare pediatric disease, and orphan drug designations.
4. Richard Fessler, MD, on Evaluating Oligodendrocyte Cell Therapy for Spinal Cord Injury
The professor of neurosurgery at Rush University Medical School discussed data seen in the phase 1/2 clinical trial of LCTOPC1.
5. Gene Therapy Fails to Improve Survival in Platinum-Resistant Ovarian Cancer
Ofra-vec continues to be evaluated in phase 2 trials for glioblastoma and colorectal cancer.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
